1h Free Analyst Time
The oral solid dosage (OSD) contract manufacturing market is forecasted to grow by USD 14.2 billion during 2023-2028, accelerating at a CAGR of 6.84% during the forecast period. The report on the oral solid dosage (OSD) contract manufacturing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by patent expiry and increasing demand for generic drugs, growing need to focus on core competencies, and availability of cost-efficient resources in emerging markets.
The oral solid dosage (OSD) contract manufacturing market is segmented as below:
By End-user
- Large-size companies
- Small and medium size companies
- Startups and generic pharmaceutical companies
By Product
- Tablets
- Capsules
- Powders
- Granules and others
By Geographical Landscape
- Asia
- North America
- Europe
- Rest of World (ROW)
The report on the oral solid dosage (OSD) contract manufacturing market covers the following areas:
- Oral solid dosage (OSD) contract manufacturing market sizing
- Oral solid dosage (OSD) contract manufacturing market forecast
- Oral solid dosage (OSD) contract manufacturing market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
360 degree market analysis
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global oral solid dosage (OSD) contract manufacturing market: AbbVie Inc., Acino International AG, Aenova Holding GmbH, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., Corden Pharma International GmbH, Inglasia Pharma Solutions, Jubilant Pharmova Ltd., Koninklijke DSM NV, Lonza Group Ltd., Merck KGaA, NextPharma GmbH, Perkin Elmer Inc., Piramal Enterprises Ltd., Pyramid Laboratories Inc., Recipharm AB, Siegfried Holding AG, Thermo Fisher Scientific Inc., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing number of US FDA-approved manufacturing facilities."
According to the report, one of the major drivers for this market is the patent expiry and increasing demand for generic drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Acino International AG
- Aenova Holding GmbH
- Beximco Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Catalent Inc.
- Corden Pharma International GmbH
- Inglasia Pharma Solutions
- Jubilant Pharmova Ltd.
- Koninklijke DSM NV
- Lonza Group Ltd.
- Merck KGaA
- NextPharma GmbH
- Perkin Elmer Inc.
- Piramal Enterprises Ltd.
- Pyramid Laboratories Inc.
- Recipharm AB
- Siegfried Holding AG
- Thermo Fisher Scientific Inc.
- Viatris Inc.
